BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28960585)

  • 21. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
    Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
    Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío IJ; Castresana JS
    Cancer Genet Cytogenet; 2007 Apr; 174(1):1-8. PubMed ID: 17350460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas.
    Terada K; Tamiya T; Daido S; Kambara H; Tanaka H; Ono Y; Matsumoto K; Ito S; Ouchida M; Ohmoto T; Shimizu K
    J Neurooncol; 2002 Jun; 58(2):107-14. PubMed ID: 12164681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1.
    Huttner AJ; Kieran MW; Yao X; Cruz L; Ladner J; Quayle K; Goumnerova LC; Irons MB; Ullrich NJ
    Pediatr Blood Cancer; 2010 Jul; 54(7):890-6. PubMed ID: 20310005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of loss of heterozygosity on chromosome 10 in human prostate carcinoma and high grade prostatic intraepithelial neoplasia].
    Wang ZM; Lai FM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct; 21(5):515-7. PubMed ID: 15476185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas.
    Fleischer M; Kessler R; Klammer A; Warnke JP; Eschrich K
    Genes Chromosomes Cancer; 2011 Dec; 50(12):1010-20. PubMed ID: 21987444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
    Xie H; Tubbs R; Yang B
    Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
    Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
    J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma.
    Alimov A; Li C; Gizatullin R; Fredriksson V; Sundelin B; Klein G; Zabarovsky E; Bergerheim U
    Anticancer Res; 1999; 19(5B):3841-6. PubMed ID: 10628321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A sequence-ready BAC clone contig of human chromosome 10p15 spanning the loss of heterozygosity region in glioma.
    Harada K; Nishizaki T; Maekawa K; Kubota H; Harada K; Suzuki M; Ohno T; Sasaki K; Soeda E
    Genomics; 2000 Aug; 67(3):268-72. PubMed ID: 10936048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
    Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
    Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and pathologic analysis of astrocytic tumors with loss of heterozygosity on chromosome 10q].
    Zhou FA; Li JZ; Ma YQ; Miao N; Liu X; Li XX; Zhang W
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):618-21. PubMed ID: 23157831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A practical review of prognostic correlations of molecular biomarkers in glioblastoma.
    Karsy M; Neil JA; Guan J; Mahan MA; Colman H; Jensen RL
    Neurosurg Focus; 2015 Mar; 38(3):E4. PubMed ID: 25727226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions.
    Daido S; Takao S; Tamiya T; Ono Y; Terada K; Ito S; Ouchida M; Date I; Ohmoto T; Shimizu K
    Oncol Rep; 2004 Oct; 12(4):789-95. PubMed ID: 15375501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.
    Liu W; James CD; Frederick L; Alderete BE; Jenkins RB
    Cancer Res; 1997 Dec; 57(23):5254-7. PubMed ID: 9393744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas.
    Maier D; Zhang Z; Taylor E; Hamou MF; Gratzl O; Van Meir EG; Scott RJ; Merlo A
    Oncogene; 1998 Jun; 16(25):3331-5. PubMed ID: 9681833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
    J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17, 19q, TP53 mutation and EGFR amplification) with short clinical course.
    Jesionek-Kupnicka D; Kulczycka D; Rieske P; Szybka M; Jabłońska J; Potemski P; Kolasa P; Liberski PP; Kordek R
    Pol J Pathol; 2007; 58(2):79-85. PubMed ID: 17715673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.